A Phase 1 Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety- and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Aligos Therapeutics2 个研究点分布在 1 个国家目标入组 20 人开始时间: 2026年1月30日最近更新: 2026年8月21日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Aligos Therapeutics
入组人数: 20
试验地点: 2
主要终点: Area under the concentration time curve [AUC]

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male and Female between 18 and 75 years old
•BMI 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb)
•Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non- sterile, male sexual partners agree to use highly effective contraceptive therapy
•Female subjects must have a negative serum pregnancy test at screening
•Inclusion Criteria for Subjects with Normal Hepatic Function:
•Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs and 12-lead electrocardiogram (ECG) assessment
•Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender
•Normal hepatic function with no known or suspected hepatic impairment
•Inclusion Criteria for Subjects with Impaired Hepatic Function:
•Subject satisfies the criteria for Class B of the Child-Pugh classification (Child Pugh Scores 7-9 points) within 28 days of study drug administration
•A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, Fibroscan, computerized tomography scan, or magnetic resonance imaging (MRI)
•Stable hepatic impairment for at least 3 months prior to screening or second screening visit to demonstrate stability
•Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria

排除标准

•for All Subjects:
•Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation
•Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc.
•Subjects with a history of clinically significant drug allergy
•Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
•Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
•Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up
•Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection. Subjects provided they met stable treatment criteria. Subjects with HIV infection may be eligible for moderate impairment cohort provided they met stable treatment criteria.
•Exclusion Criteria for Subjects with Normal Hepatic Function:
•Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the Study Review Committee (SRC), CKD-EPI should not be corrected for subjects of African ancestry
•Bilirubin (total, direct) >1.2× upper limit of normal (ULN) (unless Gilbert's is suspected)
•Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 1.2×ULN
•Grade ≥1 Hemoglobin
•Exclusion Criteria for Subjects with Impaired Hepatic Function:
•Subjects with advanced ascites (Grade 3)
•Subjects with refractory encephalopathy as judged by the investigator.
•Subjects with esophageal variceal bleeding within the past 6 months prior to screening.
•Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.
•Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the SRC, CKD-EPI should not be corrected for subjects of African ancestry
•ALT or AST level ≥5×ULN
•Serum sodium ≤125 mmol/L
•Platelets <50×10^9/L
•Grade ≥2 Hemoglobin

研究组 & 干预措施

Subjects with Hepatic Impairment

Experimental

Subjects with hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

干预措施: Pevifoscorvir Sodium (ALG-000184) (Drug)

Subjects without Hepatic impairment

Experimental

Subjects without hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium. Subjects will be followed up for 14 days after the administration of study drug.

干预措施: Pevifoscorvir Sodium (ALG-000184) (Drug)